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Background: The purpose of this study was to characterize central macular thickness and 
retinal volume following intravitreal injections using time domain and spectral domain optical 
coherence tomography (TD-OCT and SD-OCT, respectively).
Methods: Nine patients with macular edema secondary to diabetes or retinal vein occlusion 
treated with intravitreal triamcinolone 4.0 mg and/or bevacizumab 1.25 mg were enrolled. Central 
macular thickness and volume was measured by SD-OCT and TD-OCT scan at baseline, and 
1, 3, 6, 24, 48 hours, and 1 week postinjection.
Results: Equations were derived to describe central macular thickness and volume reduction 
in the hours following intravitreal injection. Measurements of central macular thickness by SD-
OCT were significantly reduced by 3 hours (P = 0.03) and retinal volume by 6 hours (P = 0.03). 
Central macular thickness measured 40.9 (28.6–53.2) µm thicker on the SD-OCT instrument 
while volume measured 3.47 (3.27–3.66) mm3 higher.
Conclusion: Significant central macular thickness and volume reductions occur in the first 
hours after injection with triamcinolone and/or bevacizumab.
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Introduction
Diabetic retinopathy and retinal vein occlusion are the leading causes of vision loss in 
working aged adults due to retinal vascular abnormalities.1–3 Macular edema is a major 
common pathway for vision loss in both these diseases.4 Laser photocoagulation has 
been the mainstay of treatment for both diabetic macular edema and macular edema 
secondary to branch but not central retinal vein occlusion.3,5–7 However, recent studies 
have shown that intravitreal delivery of corticosteroids and antivascular endothelial 
growth factor (VEGF) agents can provide significant visual benefits for branch and 
central retinal vein occlusion.8–12
The corticosteroid most often used for intravitreal injections is triamcinolone 
because of its long therapeutic response of up to 3 months.13 Ranibizumab (rhuFab 
V2, Lucentis®, Genentech, South San Francisco, CA) is the affinity-matured anti-
VEGF antibody recently approved for retinal vein occlusion.11,12 The full-length 
antibody, bevacizumab (Avastin®, Genentech, South San Francisco, CA), is commonly 
used off-label.14 These agents are effective in improving visual acuity and reducing 
macular edema associated with diabetic retinopathy and retinal vein occlusion in 
prospective randomized trials.15–23 However, a durable effect is often not achieved, 
with macular edema recurring after several months, and retreatment is required.18,24 
When both triamcinolone and bevacizumab were used in a combined injection, visual 
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improvement was faster but the added benefit disappeared in 
longer follow-up.25 Compared with laser photocoagulation, 
intravitreal injections may be more effective in the months 
after intervention, but laser may offer better visual outcomes 
in the following years.26,27 A recent trial suggests that a 
combined therapeutic approach using intravitreal ranibizumab 
or triamcinolone injections for their short-term effects and 
laser for long-term control may be optimal.28 However, the 
most cost-effective and convenient approach from both the 
patient and physician perspective remains unclear.
A better understanding of the immediate effects of these 
drugs would provide insight into their mechanisms of action 
and could lead to the development of more targeted and 
effective treatments. Additionally, it may help clarify the 
role of each type of therapeutic intervention, elucidating the 
optimal dosing regimens for patients. This pilot study used 
spectral domain optical coherence tomography (SD-OCT) to 
characterize short-term changes in macular thickness in the 
first hours and days following a single intravitreal injection 
of one or both of these agents, and investigated potential 
measurement differences between two widely used OCT 
methods, ie, SD-OCT and time domain OCT (TD-OCT).
Materials and methods
The research protocol for this observational study was 
approved by the Stanford University School of Medicine 
Institutional Review Board. A total of 45 patients with 
macular edema secondary to either diabetic retinopathy 
or retinal vein occlusion were identified by computerized 
review of patient records and were asked to participate in 
the study between November and December 2008. Patients 
who were pregnant were excluded from the study, as were 
children. An initial power calculation using a power of 80% 
and significance level of 0.05 indicated that approximately 
10 patients were needed to determine a central macular 
thickness difference of 90 µm with a standard deviation of 
100 µm, as had been shown in previous studies.25,29 A total of 
nine patients were able to be enrolled during the study period, 
of which six were treated with intravitreal   triamcinolone 
4.0 mg alone (including five with diabetic macular edema). 
Of the four patients with retinal vein occlusion, one had 
branch vein occlusion and three had central vein occlusion. 
The patient with branch retinal vein occlusion received 
bevacizumab 1.25 mg. For the three patients with central 
retinal vein occlusion, one received triamcinolone 4.0 mg, 
one received bevacizumab 1.25 mg, and one received both 
agents simultaneously. The clinical judgment of the treating 
physician determined the type of injection given to the 
patients; all had previously received some sort of intravitreal 
injection. A summary of each patient’s disease process and 
injection received can be found in Table 1.
Imaging was performed using TD-OCT (Stratus OCT 
Software Version 5.0 Carl Zeiss Meditec, Dublin, CA) 
and SD-OCT (Cirrus HD-OCT Software Version 3.0; Carl 
Zeiss Meditec) prior to injection and then at 1 hour, 3 hours, 
6–9 hours, 1 day, 2 days, and 1 week after injection. A six-
line fast macular scanning protocol was used for the TD-OCT 
device and a 512 × 128 macular cube protocol was used for 
the SD-OCT device. Snellen visual acuity with pinhole was 
recorded before each scan. Additional SD-OCT scans were 
obtained from seven patients at their final visit 4–6 weeks later. 
Figure 1 shows an example of the SD-OCT images   collected 
for patients 5 and 8. After the first patient, the   following four 
patients with diabetic retinopathy had   imaging performed on 
both eyes so that the fellow (noninjected) eye could serve as a 
control for any fluctuations in levels of macular edema.
Table 1 Summary of disease process, injection, visual acuity, and calculated coefficient for exponential decline in macular edema in 
enrolled patients 48 hours after treatment
Patient Disease Drug Baseline VA VA after  
1 week
Baseline 
CMT (μm)
CMT after 
48 hours
CMT after  
1 week
Coefficient 
(per hour)
R2 95% CI  
(per hour)
1 D* T 20/400 +1 20/400 +1 706 528 459 -0.007 0.97 -0.009 to -0.005
2 D* T 20/100 20/70 -2 271 271 253 0.002 0.03 -0.005 to 0.009
3 CV T, B 20/150 20/100 +1 697 318 250 -0.013 0.74 -0.025 to -0.001
4 BV* B 20/40 +2 20/20 377 292 285 -0.010 0.67 -0.021 to 0.001
5 CV T CF at 2 feet CF at 6 feet 1141 266 251 -0.036 1.00 -0.040 to -0.032
6 D T 20/100 +1 20/40 +1 737 479 347 -0.005 0.94 -0.007 to -0.003
7 D* T 20/40 +1 20/25 -2 408 358 360 -0.005 0.94 -0.006 to 0.03
8 CV B CF at 4 feet CF at 6 feet 716 258 164 -0.025 0.99 -0.029 to 0.020
9 D* T 20/80 20/70 -2 529 468 420 -0.002 0.43 -0.005 to 0.001
Notes: Baseline CMT measurements are given from SD-OCT. *indicates that patient also had an epiretinal membrane.
Abbreviations: D, diabetes mellitus; CF, count fingers; CV, central retinal vein occlusion; BV, branch retinal vein occlusion; T, triamcinolone 4 mg; B, bevacizumab 1.25 mg; 
CI, confidence interval; VA, visual acuity; CMT, central macular thickness; SD-OCT, spectral domain optical coherence tomography.
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Software-generated measurements for central subfield 
mean thickness were recorded as central macular thickness. 
Central macular thickness and macular volume measure-
ments at each time point were plotted and fitted to both an 
exponential and linear regression model to determine the 
rate of reduction in the first 24 and 48 hours after injection. 
Results for each individual patient were then averaged to 
generate a mean and confidence interval for the measurement. 
Individual scans on the SD-OCT instrument were reviewed 
and any abnormalities in the segmentation software that 
would have resulted in incorrect calculations of central macu-
lar thickness and macular volume were manually corrected 
using the analysis software for two of the 91 scans collected in 
this study. Lines from the TD-OCT scans with gross errors in 
automated segmentation were discarded, because the review 
software did not have an editing feature. Paired t-tests were 
used to determine the time at which the reduction in central 
macular thickness and macular volume became significant. 
Data were analyzed for each injection type and disease 
process separately, and also for all nine patients together 
using the Analyse-It software program (Analyse-It Software, 
Leeds, UK). Both percent and absolute changes are reported 
because it has been shown that absolute changes in thickness 
are the preferred measure in mild thickening, and relative 
change is preferred in more severe thickening.30 The mean 
difference in central macular thickness and volume measure-
ments from both instruments were compared to determine if 
a systematic difference in measurement existed for patients 
with macular edema.
Results
The mean age of the patients in this study was 70.6 
(55–82) years; six were female and three were male. 
Table 1 summarizes the disease, injection type, and visual 
acuity for each patient, as well as the extent to which they 
could be fit to a regression model. Baseline visual acuity 
was correlated with central macular thickness, with a linear 
coefficient of 0.68. When central macular thickness was 
tracked over time,   correlation coefficients were uniformly 
higher for exponential than for linear regressions, and only 
the   exponential coefficients are displayed. All patients except 
patient 1 displayed some improvement in visual acuity in 
the first week after their intravitreal injection. All patients 
except for patient 2 showed a negative correlation coefficient, 
indicating an exponential reduction in central macular 
thickness during the first 48 hours following an injection. 
Patient 2 (regression coefficient 0.002 per hour) also had 
the lowest correlation coefficient (R2 = 0.03). Five patients 
had correlation coefficients greater than 0.9 (patient 1 and 
patients 5–8), and of these, two were perfectly described 
by an exponential function (patients 5 and 8). One of the 
remaining patients had a correlation coefficient less than 
0.5 (patient 9), while the coefficient for the other two was 
approximately 0.7 (patients 3 and 4). The aggregate data for 
all patients by injection and by disease process medication 
is shown in Table 2. When separated into subgroups, the 
confidence intervals for the coefficient of reduction in central 
macular thickness include 0. However, when the patients are 
analyzed together, the exponential coefficient of reduction 
was -0.010 (-0.018 to -0.002) per hour (R2 = 0.83). Figure 2 
is a graphical representation of the central macular thickness 
for each patient in the first 48 hours after their injection.
Volume measurements were more poorly described by 
both exponential and linear regression models, although again 
the exponential regression produced higher correlation coef-
ficients. Four patients had correlation coefficients less than 
0.5. Three patients had correlation coefficients between 0.7 
and 0.9 (patients 3, 6, and 8) and two patients had correlation 
coefficients greater than 0.9 (patients 1 and 5). Again, the con-
fidence interval included 0 when patients were separated by 
Figure 1 representative spectral domain optical coherence tomography scans from two patients showing the macula at (A) prior to intravitreal injection, (B) 1 hour, 
(C) 3 hours, (D) 6–9 hours, (E) 24 hours, (F) 48 hours, (G) 1 week, and (H) 1 month following injection. Patient 5 (top) received an injection of triamcinolone 4.0 mg while 
patient 8 (bottom) received bevacizumab 1.25 mg.
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injection type and disease process, but when all the data were 
combined, the average exponential coefficient of reduction 
was -0.005 (-0.009 to -0.0002) per hour (R2 = 0.34).
Table 3 displays the mean reduction in central macular 
thickness in the hours to days after intravitreal injections 
measured by both the TD-OCT and SD-OCT devices. 
A statistically significant reduction was found by the 
SD-OCT instrument starting at 3 hours after injection 
(P = 0.027) and persisted throughout the following period. 
By 48 hours, the mean reduction in central macular thickness 
was 260.44 (46.41–474.47) µm (33.51%). This accounted 
for 80% of the eventual reduction achieved in a week, ie, 
310.33 (88.56–532.11) µm (41.17%). However, on the TD-
OCT instrument, a significant reduction was not seen until 
24 hours (P = 0.035) or longer after injection. At 48 hours 
after injection, the mean reduction was 259.78 (72.75–
446.81) µm (37.92%) or 90% of the reduction achieved at 
1 week. When the data were separated by injection types, 
the statistical significance disappeared for scans taken from 
both machines as the group sizes were not powered to detect 
a difference. Additionally, when the data were separated 
by disease process as shown in Table 4, there was a sig-
nificant difference in central macular thickness starting at 
3 hours for patients with diabetic retinopathy and 6 hours 
for those with retinal vein occlusion (P = 0.003, P = 0.048, 
respectively). However, this difference between the groups 
was no longer significant after 24 hours, although the mean 
difference continued to grow larger. No significant trends 
were observed in the four diabetic patients whose fellow 
eyes with macular edema were also scanned as a control 
for variations in macular edema as the natural progression 
or fluctuation of the disease.
Reductions in macular volume were also evaluated 
and showed similar trends. The reduction in volume 
seen on SD-OCT scans reached statistical significance at 
6 hours (P = 0.031), while the mean difference was 0.89 
(0.11–1.67) mm3 (5.42%). At 48 hours, volume reduction was 
3.20 (0.27–6.13) mm3 (17.90%). This was over 80% of the 
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Figure 2 reduction in central macular thickness in the first 48 hours after injection. 
Abbreviation: CMT, central macular thickness.
Table 2 Exponential regression coefficients for the first 48 hours 
after injection shown for all patients combined and also divided by 
treatment and by disease process
Coefficient  
of reduction  
(per hour)
Average  
R2
95% CI  
(per hour)
All injections  
combined (n = 9)
-0.010 0.83 -0.018 to -0.002
Triamcinolone  
4 mg (n = 6)
-0.008 0.78 -0.020 to 0.004
Bevacizumab  
1.25 mg (n = 2)
-0.014 0.74 -0.111 to 0.083
Diabetic  
retinopathy (n = 5)
-0.004 0.69 -0.001 to 0.003
retinal vein  
occlusion (n = 4)
-0.018 0.90 -0.085 to 0.049
Abbreviation: CI, confidence interval.
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  reduction in volume reached in 1 week, 3.88 (0.85–6.91) mm3 
(22.21%). The TD-OCT instrument did not show a significant 
change until 24 hours after the injection (P = 0.041). Similar 
to the SD-OCT scans, at 48 hours after injection, volume was 
reduced by 3.39 (0.74–6.04) mm3 (25.08%). This was over 
80% of the reduction in volume achieved in a week, ie, 3.10 
(0.10–6.09) mm3 (21.80%). When analyzed separately by 
type of injection and by disease, none of the reductions in 
macular volume were statistically significant.
Compared with the CMT measurements made by the TD-
OCT instrument, SD-OCT measurements were on average 
40.9 (28.6–53.2) µm thicker (n = 84, all scans). The SD-OCT 
instrument also calculated a greater volume, on average 3.47 
(3.27–3.66) mm3 higher than TD-OCT data.
Discussion
The results reported here indicate that the reduction in cen-
tral macular thickness occurs rapidly in the first few hours 
after intravitreal drug injection and generally follows an 
exponential rather than linear decay. This suggests that the 
drugs may immediately change the permeability of the retinal 
pigment epithelium to fluid movement or can recruit pumps 
to expel accumulated proteins and fluid actively. The rate of 
reduction in central macular thickness is best described by 
the following exponential function:
[Central macular thickness = baseline central   macular 
  thickness* exp (-0.01/hour* postinjection)]
Volume   measurement data were less consistent, but can be 
described by the   equation: 
  [Volume = baseline volume* exp (-0.006/hour* 
postinjection)]
Prior studies by Marmor have determined 0.1 µL/hour/
mm2 to be the rate at which the retinal pigment   epithelium 
is capable of pumping out fluid, or an expected reduction of 
0.1 mm3/hour in the 1 mm2 space of measurement for central 
macular thickness.31 Even higher flow rates are achievable 
when the retina is damaged, like in retinal detachments, 
and passive transport is the predominant force driving fluid 
movement.31 Our study found a linear rate of reduction of 
-0.066 mm3/hour or an exponential   coefficient -0.0005 per 
hour, a very similar rate to the one reported previously. This 
suggests that intravitreal   triamcinolone and bevacizumab 
injections may be enhancing some mechanism of active 
transport to cause efflux of macular edema fluid. Blood retinal 
Table 3 Pooled data for mean reduction (n = 9) in central macular thickness compared with baseline measurements made before 
injection on both SD-OCT and TD-OCT instruments
Time  
postinjection
Mean reduction  
in SD-OCT (μm)
95% CI P value Mean reduction  
in TD-OCT (μm)
95% CI P value
0 hoursa 620.22 – – 574.56 – –
1 hour 22.44 -9.82 to 174.45 0.147 42.33 -8.49 to 209.92 0.091
3 hours 55.22 8.22 to 102.23 0.027* 50.44 -36.75 to 137.64 0.219
6 hours 71.56 11.85 to 131.26 0.025* 75.00 -7.93 to 157.93 0.071
24 hours 173.67 12.42 to 334.92 0.038* 171.56 15.73 to 327.38 0.035*
48 hours 260.44 46.41 to 474.47 0.023* 259.78 72.75 to 446.81 0.013*
1 week 310.33 88.56 to 532.11 0.012* 285.56 91.48 to 479.63 0.010*
Notes: aValue reported at 0 hours is the mean central macular thickness of all patients at baseline; *P , 0.05.
Abbreviations: CI, confidence interval; SD-OCT, spectral domain optical coherence tomography; TD-OCT, time domain optical coherence tomography.
Table 4 Data for mean reduction in central macular thickness compared with baseline measurements before injection in patients with 
diabetic retinopathy or retinal vein occlusion
Time  
postinjection
Mean reduction  
in DR, n = 5 (μm)
95% CI P value Mean reduction  
in RVO, n = 4 (μm)
95% CI P value
0 hoursa 530.2 – – 732.75 – –
1 hour 11.0 -3.4 to 25.4 0.101 36.8 -64.3 to 137.8 0.331
3 hours 23.0 13.1 to 32.9 0.003* 95.5 -27.7 to 218.7 0.090
6 hours 22.6 2.2 to 43 0.037* 132.8 2.1 to 263.4 0.048*
24 hours 56.0 -8.1 to 120.1 0.072 320.8 -75.1 to 716.6 0.082
48 hours 109.4 -21.8 to 240.6 0.082 449.3 -69.6 to 968.1 0.070
1 week 162.4 -29.7 to 354.5 0.079 495.3 -27.7 to 1018.2 0.057
Notes: aValue reported at 0 hours is the mean CMT of all patients at baseline; *P , 0.05.
Abbreviations: CI, confidence interval; DR, diabetic retinopathy; RVO, retinal vein occlusion.
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junctions in this case are likely intact and passive forces do 
not come into play.
The focus of previous pharmacokinetic studies has been 
the period of time in which an agent remains in the vitreous. 
Studies of high-dose triamcinolone injections (20–25 mg) 
showed that the steroid is still detectable in eyes without 
prior vitrectomy even a year and a half after the injection, and 
for 3 or more months afterwards in eyes that had undergone 
vitrectomy.24,32,33 Bevacizumab 1.5 mg has been shown to have 
an aqueous half-life of 9.8 days.34 Given the different rates 
of clearance of these agents, it seems worthwhile to compare 
the rates at which they act in the initial period. It has been 
hypothesized that corticosteroids may act by inhibiting the 
VEGF gene or by modulating the effector proteins related 
to the VEGF signaling pathway.13 A similar drug effect time 
would be evidence in support of the two agents affecting a 
common pathway. The results in this study suggest that this 
is possibly the case; the rates of reduction in macular edema 
are likely to be comparable between patients receiving intra-
vitreal triamcinolone and bevacizumab.
This study also reveals that significant reductions in 
both central macular thickness and macular volume occur 
as early as the first 6 hours after an intravitreal injection. 
While study enrollment was insufficiently powered to detect 
differences in patients receiving triamcinolone 4.0 mg alone 
or bevacizumab 1.25 mg alone, the pooled data strongly 
suggest that a robust change occurred rapidly in the injected 
eyes. When the data were separated by disease process, an 
initially significant change at 3 and 6 hours occurred, but 
because of the lack of power and increase in variance, the 
calculations after 24 hours were no longer significant, even 
though the mean difference grew larger. After 1 week, 
patients on average saw a reduction of 41% in their central 
macular thickness, with over half of this change occurring 
in the first day and 80% of the change by 48 hours. Further, 
patients generally had an improvement in Snellen visual 
  acuity measured at these visits. Only patient 1 experienced no 
change in visual acuity, despite having a dramatic reduction 
in her central macular thickness from 706 µm to 459 µm. 
However, she had long-standing, poorly controlled disease 
previously treated with vitrectomy and extensive peripheral 
ischemia on fluorescein angiography, severely limiting her 
visual potential. Previous studies have shown that patients 
with ischemic central retinal vein occlusion do not respond 
to triamcinolone injections, while those with nonischemic 
central retinal vein occlusion do respond.18 It may be that the 
degree of ischemic damage already incurred in the retina is 
the limiting factor for response. Only patient 2 experienced 
no reduction in central macular thickness, although he did 
have an improvement in visual acuity. He did not have 
extensive areas of ischemia by fluorescein angiography. 
He did start with a relatively more normal central macular 
thickness measurement (271 µm) which left relatively little 
headroom for a statistically significant decrease in central 
macular thickness compared with the other eight patients, all 
of whom had considerably larger starting values for central 
macular thickness. Studies have also shown that the link 
between visual acuity and macular thickness may be tenuous, 
with only a modest correlation between best corrected visual 
acuity and macular thickness.35,36
It is also interesting to note that patient 2 had a correla-
tion coefficient of 0.03 when fit to an exponential curve and 
patient 9 had a correlation of 0.43. This suggests that there 
may be infrequent nonresponders to triamcinolone 4.0 mg 
injections. Because there were only two patients who received 
bevacizumab 1.25 mg injections, it is difficult to determine 
whether this phenomenon is also true for that drug, although 
there is anecdotal evidence for this phenomenon in some 
diabetic patients, at least for single injections. This effect 
will be important to understand in order to optimize treat-
ment schedules for patients and eliminate injections that do 
not benefit patients. The results of this study indicate that 
responders to treatment would likely show a change within 
hours of the injection. Future studies can evaluate if a strategy 
of remeasuring central macular thickness within 24–48 hours 
and choosing an alternative agent in nonresponders would lead 
to better resolution of macular edema and improved visual 
outcomes. A study with longer follow-up would also be help-
ful to evaluate whether the initial response is predictive of 
long-term sustainability of the reduction in macular edema.
Previous studies and meta-analyses have determined that 
patients often see an improvement in the months following an 
injection, and many need repeated injections for a sustained 
effect.20,37 A 2007 DRCRnet study showed that patients 
receiving bevacizumab 1.25 mg and 2.25 mg injections had 
greater reductions in central macular thickness than those 
who received laser treatment. These patients also had better 
improvements in visual acuity at 12 weeks with no short-term 
benefits of combining laser and bevacizumab injections.38 
Laser photocoagulation was also shown to be less effective 
than triamcinolone 4.0 mg injections in the short term, but the 
effect was no longer present at 1 year and even reversed later, 
with patients receiving laser having better visual outcomes 
after 2 years.26,27 Based on those results and the preliminary 
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results generated from this study, similar mechanisms may 
be activated by both injection types.
It is possible that the effects of triamcinolone are more 
short-term than those of bevacizumab, but this is yet to be 
shown in a prospective comparison. Overall, it appears that 
intravitreal injections of anti-VEGF agents and corticosteroids 
could be used for their short-term effects (days and weeks) to 
reduce macular edema to a level at which laser photocoagula-
tion can be considered to achieve long-term control (years and 
more). A recent DRCRnet study was performed to evaluate 
the efficacy of such a combination approach, using intravitreal 
triamcinolone or ranibizumab injections for their short-term 
effects and laser for long-term control. Participants were 
randomized to sham injection and prompt laser, ranibizumab 
0.5 mg and prompt laser, ranibizumab 0.5 mg and delayed 
laser, or triamcinolone 4.0 mg and prompt laser. Patients 
who received drug injections and laser treatments had more 
reduction in central macular thickness than those who received 
sham injections and laser after one and 2 years.28
Since the initiation of this study, more work has been 
done to understand the measurement differences between 
the Stratus and the Cirrus OCT systems. Kiernan et al 
found that in conditions of increased macular thickness, the 
thickness measured by the Cirrus is 43 µm greater than the 
Stratus, likely due to measurement differences built into the 
detection algorithms of the machines.39 Our study showed 
a similar increase in thickness of 40.9 µm and a volume of 
3.47 (3.27–3.66) µm3 higher.
The conclusions able to be drawn from this study are 
limited by the small sample size. While 45 patients were 
approached to participate, only nine were enrolled because of 
the time commitment on the day of injection and for follow-up 
visits. However difficult the recruitment, it would be valuable 
to pursue future investigations involving more patients receiv-
ing each type of injection and underlying disease processes. 
An effective treatment strategy could be determined more 
rapidly because it appears that patients who are destined to 
respond to treatment are likely to declare themselves within 
the first 24 hours after receiving an intravitreal injection of 
triamcinolone or bevacizumab. Additionally, further studies 
could lead to new insights into the mechanism of action of 
different therapies for macular edema, paving the way for the 
development of more targeted therapeutics.
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